Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CTNNB1 amp||acute myeloid leukemia||predicted - sensitive||CWP232291||Phase I||Actionable||In a Phase I trial, CWP232291 reduced beta-catenin expression and demonstrated safety and preliminary efficacy in acute myeloid leukemia (J Clin Oncol (Meeting Abstracts) 2015 33: 7044)).||detail...|
|PubMed Id||Reference Title||Details|
|Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).||Full reference...|